Federal Register / Vol. 80, No. 59 / Friday, March 27, 2015 / Notices 16389 

corporations: 15.15 hours; investment 

Edge and agreement corporations: 9.60 

hours. 

Number of respondents: Banking Edge 

and agreement corporations (quarterly): 

7; banking Edge and agreement 

corporations (annual): 1; investment 

Edge and agreement corporations 

(quarterly): 20; investment Edge and 

agreement corporations (annual): 19. 

General description of report: This 

information is mandatory (12 U.S.C. 

602, 625). In addition, with respect to 

the contact information collected in the 

Patriot Act Contact Information section, 

the Board’s regulation’s (12 CFR part 

211.5(m)) instruct Edge and agreement 

corporations to comply with the 

information sharing regulations that the 

Department of the Treasury issued 

pursuant to Section 314(a) of the USA 

Patriot Act of 2001, Public Law 107–56, 

115 Stat. 307 (31 U.S.C. 5318(h)); and 

implemented at 31 CFR part 

1010.520(b). 

For Edge corporations engaged in 

banking, current Schedules RC–M (with 

the exception of item 3) and RC–V are 

held confidential pursuant to Section 

(b)(4) of FOIA (5 U.S.C. 552(b)(4)). For 

investment Edge corporations, only 

information collected on Schedule RC– 

M (with the exception of item 3) are 

given confidential treatment pursuant to 

Section (b)(4) of FOIA (5 U.S.C. 

552(b)(4)). 

In addition, the information provided 

in the Patriot Act Contact Information 

section may be withheld as confidential 

under FOIA to prevent unauthorized 

individuals from falsely posing as an 

institution’s point-of-contact in order to 

gain access to the highly sensitive and 

confidential communications sent by 

email between the Financial Crimes 

Enforcement Network or federal law 

enforcement officials and the Patriot Act 

point-of-contact. The identity and 

contact information of private 

individuals, which is collected and 

maintained for law enforcement 

purposes under the Patriot Act, may be 

exempt from disclosure pursuant to 

exemption 7(C) of FOIA (5 U.S.C. 

552(b)(7)(C)). Lastly, the language 

indicating that the Emergency Contact 

information will not be released to the 

public will be removed. 

Abstract: The FR 2886b collects 

quarterly financial data from banking 

Edge and agreement corporations and 

investment (nonbanking) Edge and 

agreement corporations. Except for 

examination reports, it provides the 

only financial data available for these 

corporations. The Federal Reserve is 

solely responsible for authorizing, 

supervising, and assigning ratings to 

Edge and agreement corporations. The 

Federal Reserve uses the data collected 

on the FR 2886b to identify present and 

potential problems and monitor and 

develop a better understanding of 

activities within the industry. 

Current Actions: The Federal Reserve 

proposes to add questions regarding 

confidential treatment in the form of 

check boxes to all of the reports listed 

above so institutions may indicate 

whether they are requesting confidential 

treatment for any portion of the data 

provided, and whether they are 

submitting a formal justification with 

the data or separately. The proposed 

revision would enhance existing 

processes related to the handling of data 

confidentiality requests. The questions 

regarding confidential treatment in the 

form of check boxes would be effective 

June 30, 2015. 

Board of Governors of the Federal Reserve 

System, March 24, 2015. 

Robert deV. Frierson, 

Secretary of the Board. 

[FR Doc. 2015–07067 Filed 3–26–15; 8:45 am] 

BILLING CODE 6210–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of Exclusive 

License: Small Molecule Therapeutics 

Against Hepatitis C Virus Infection 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: This is notice, in accordance 

with 35 U.S.C. 209 and 37 CFR part 404, 

that the National Institutes of Health, 

Department of Health and Human 

Services, is contemplating the grant of a 

start-up exclusive commercial patent 

license agreement to practice the 

inventions embodied in U.S. provisional 

patent application no. 61/909,414 (NIH 

Ref. No. E–011–2014/0–US–01) filed 

November 27, 2013; International PCT 

application no. PCT/US2014/066680 

(NIH Ref. No. E–011–2014/0–PCT–02) 

filed November 20, 2014; Taiwanese 

patent application no. 103141004 (NIH 

Ref. No. E–011–2014/0–TW–03) filed 

November 26, 2014; and U.S. 

provisional patent application no. 62/

011,462 (NIH Ref. No. E–161–2014/0– 

US–01) filed June 12, 2014; all entitled, 

‘‘Heterocyclic Compounds and Methods 

of Use Thereof;’’ and all continuing 

applications and foreign counterparts to 

Virotas Biopharmaceuticals, LLC, a 

company having a place of business in 

California. The patent rights in these 

inventions have (a) been assigned to the 

United States of America, as represented 

by the Secretary, Department of Health 

and Human Services who has delegated 

authority for the licensing of inventions 

to the National Institutes of Health or (b) 

been exclusively licensed to the 

National Institutes of Health. 

The prospective exclusive license 

territory may be ‘‘worldwide’’, and the 

field of use may be limited to the 

following: ‘‘Prevention and treatment of 

Hepatitis C Virus infection.’’ 

DATES: Only written comments and/or 

applications for a license which are 

received by the NIH Office of 

Technology Transfer on or before April 

13, 2015 will be considered. 

ADDRESSES: Requests for copies of the 

patent application, inquiries, comments, 

and other materials relating to the 

contemplated exclusive license should 

be directed to: Kevin W. Chang, Ph.D., 

Senior Licensing and Patenting 

Manager, Office of Technology Transfer, 

National Institutes of Health, 6011 

Executive Boulevard, Suite 325, 

Rockville, MD 20852–3804; Telephone: 

(301) 435–5018; Facsimile: (301) 402– 

0220; Email: changke@mail.nih.gov. 

SUPPLEMENTARY INFORMATION: The 

subject technologies are small molecule 

compounds for the treatment of HCV 

infection identified using a novel cellbased high throughput assay. Some of 

these compounds are derivatives of 

chlorcyclizine that show potent 

antiviral properties against HCV. 

Chlorcyclizine is already on the market 

for the treatment of allergic reactions, 

have been used extensively in humans, 

and have excellent safety profiles with 

known pharmaceutical properties. The 

other compounds are also heterocyclic 

compounds that show anti-HCV 

activity. The subject technologies can 

potentially be used in combination with 

each other and/or with other HCV 

therapeutics. 

The prospective start-up exclusive 

commercial patent license will be 

royalty bearing and will comply with 

the terms and conditions of 35 U.S.C. 

209 and 37 CFR part 404. The 

prospective start-up exclusive 

commercial patent license may be 

granted unless within fifteen (15) days 

from the date of this published notice, 

the NIH receives written evidence and 

argument that establishes that the grant 

of the license would not be consistent 

with the requirements of 35 U.S.C. 209 

and 37 CFR part 404. 

Applications for a license in the field 

of use filed in response to this notice 

will be treated as objections to the grant 

of the contemplated exclusive license. 

Comments and objections submitted to 

this notice will not be made available 

mstockstill on DSK4VPTVN1PROD with NOTICES

16390 Federal Register / Vol. 80, No. 59 / Friday, March 27, 2015 / Notices 

for public inspection and, to the extent 

permitted by law, will not be released 

under the Freedom of Information Act, 

5 U.S.C. 552. 

Dated: March 23, 2015. 

Richard U. Rodriguez, 

Acting Director, Office of Technology 

Transfer, National Institutes of Health. 

[FR Doc. 2015–06974 Filed 3–26–15; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[30Day–15–15CF] 

Agency Forms Undergoing Paperwork 

Reduction Act Review 

The Centers for Disease Control and 

Prevention (CDC) has submitted the 

following information collection request 

to the Office of Management and Budget 

(OMB) for review and approval in 

accordance with the Paperwork 

Reduction Act of 1995. The notice for 

the proposed information collection is 

published to obtain comments from the 

public and affected agencies. 

Written comments and suggestions 

from the public and affected agencies 

concerning the proposed collection of 

information are encouraged. Your 

comments should address any of the 

following: (a) Evaluate whether the 

proposed collection of information is 

necessary for the proper performance of 

the functions of the agency, including 

whether the information will have 

practical utility; (b) Evaluate the 

accuracy of the agencies estimate of the 

burden of the proposed collection of 

information, including the validity of 

the methodology and assumptions used; 

(c) Enhance the quality, utility, and 

clarity of the information to be 

collected; (d) Minimize the burden of 

the collection of information on those 

who are to respond, including through 

the use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submission of 

responses; and (e) Assess information 

collection costs. 

To request additional information on 

the proposed project or to obtain a copy 

of the information collection plan and 

instruments, call (404) 639–7570 or 

send an email to omb@cdc.gov. Written 

comments and/or suggestions regarding 

the items contained in this notice 

should be directed to the Attention: 

CDC Desk Officer, Office of Management 

and Budget, Washington, DC 20503 or 

by fax to (202) 395–5806. Written 

comments should be received within 30 

days of this notice. 

Proposed Project 

Health Insurance Plans Research 

Study—New—Office of Health System 

Collaboration, Office of the Associate 

Director for Policy, Office of the 

Director, Centers for Disease Control 

and Prevention (CDC). 

Background and Brief Description 

The CDC Office of the Associate 

Director for Policy intends to request 

that the Office of Management and 

Budget (OMB) approve a new collection 

of information under the Paperwork 

Reduction Act for three years. This data 

collection will occur once, and 

respondents will be surveyed once. 

The Health Insurance Plans Research 

Study will uniquely examine the 

prevalence, characteristics, and 

differences of prevention and wellness 

programs offered by health insurance 

plans in this critical era of healthcare 

reform. There are no known studies that 

have addressed the prevalence of 

prevention and wellness programs 

across health plans or explored the 

granular details of these programs as 

this study is intended to do. Not 

conducting this study would be one less 

step toward increasing healthy years of 

life. 

Furthermore, the Health Insurance 

Plans Research Study will address the 

priorities and goals of the CDC Office of 

the Associate Director for Policy, Office 

of Health System Collaboration: (a) 

Identify and catalyze policy 

opportunities such as the Affordable 

Care Act to enhance healthcare 

transformation, (b) advance CDC’s 

public health-healthcare strategy to 

improve population health, (c) 

strengthen strategic partnerships with 

healthcare systems and payers, federal 

and non-federal, and (d) fully leverage 

performance measures as a tool to 

improve the health of individuals across 

health systems and payers. 

The results of this study are of great 

interest not only to the CDC Office of 

the Associate Director for Policy but to 

other CDC Centers, Institutes, and 

Offices; and other federal agencies and 

partners such as the Health Resources 

and Services Administration (HRSA), 

the members of the CDC Advisory 

Committee to the Director, and the CDC 

Public Health-Health Care Collaboration 

Workgroup (federal, state, and local 

public health; public and private 

organizations; healthcare providers; 

professional membership associations; 

and academia representation). 

CDC will select a sample of 

approximately 150 commercial health 

insurance plans in the United States 

that differ by size and geography, in the 

50 states and the District of Columbia, 

to complete a web-based survey, the 

Prevention and Wellness Assessment 

Survey. The project team will provide 

information and instructions about the 

survey to health plan points of contact 

in advance. The team will also make 

information and instructions available 

on the Web site, eliminating any 

interactions between the respondent 

and the project team, unless a 

respondent(s) has questions or concerns 

during completion of the survey. 

The Prevention and Wellness 

Assessment Survey will take 

approximately 30 minutes to complete 

per respondent for a total estimated 

burden of 75 hours. Key health plan 

contacts (e.g., medical directors, nurse 

directors, or other healthcare 

professional) will incur burden 

associated with coordinating the time 

and identifying a person to take the 

survey. The burden associated with this 

activity is estimated at 30 minutes per 

key health plan contact for a maximum 

of one key contact per health plan (1 key 

contact × 150 health plans = 150 key 

contacts), resulting in a total burden of 

75 hours. In addition, administrative 

support staff at select health plans may 

assist with coordinating 

communications between key health 

plan points of contact and America’s 

Health Insurance (AHIP). The estimated 

administrative support burden is 30 

minutes per health plan, resulting in a 

total burden of 75 hours. 

Following the analysis of survey data, 

the project team will conduct one-hour 

telephone interviews with no more than 

nine health plans (1 hour × 9 health 

plans) to gain a better understanding of 

lessons learned and best practices 

associated with the design and 

implementation of prevention and 

wellness programs by commercial 

health insurance plans. The project 

team will use this information to build 

upon the knowledge gained through the 

survey. For example, there may be 

differences in how health plans 

structure prevention and wellness 

programs for different employer 

accounts based on employer requests. 

The estimated burden is one hour per 

health plan, resulting in a total burden 

of nine hours. 

Best practices in outreach will be 

utilized to maximize survey response 

rates. Key health plan contacts at nonresponding health plans will receive 

follow up by telephone, and one-to-one 

assistance will be provided if needed. 

mstockstill on DSK4VPTVN1PROD with NOTICES